Acepodia
IPO- Employees
- 51–200
- Business Model
- B2B
- Website
- acepodia.com
- Total Funding
- $266.0M
- Last Round
- $100.0M Series DMar 2023
- Rounds
- 4
- Type
- Public
About
Clinical-stage biotechnology company developing first-in-class cell therapies with enhanced tumor-killing potency for cancer.
Summary
Acepodia is a Biotech company based in United States. It has raised $266.0M in total across 4 rounds, most recently a $100.0M Series D round in Mar 2023. Investors include Ridgeback Capital, 8VC and DEFTA Partners.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Mar 2023
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Food technology company creating plant-based meat and dairy products that replicate the taste and...